142 related articles for article (PubMed ID: 37093417)
1. Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors.
C AM; Wessler S; Ponnuraj K
Protein J; 2023 Aug; 42(4):343-354. PubMed ID: 37093417
[TBL] [Abstract][Full Text] [Related]
2. The proteolytic activity of Listeria monocytogenes HtrA.
Abfalter CM; Bernegger S; Jarzab M; Posselt G; Ponnuraj K; Wessler S
BMC Microbiol; 2019 Nov; 19(1):255. PubMed ID: 31726993
[TBL] [Abstract][Full Text] [Related]
3. High Temperature Requirement A (HtrA) protease of Listeria monocytogenes and its interaction with extracellular matrix molecules.
Radhakrishnan D; M C A; Hutterer E; Wessler S; Ponnuraj K
FEMS Microbiol Lett; 2021 Nov; 368(20):. PubMed ID: 34755852
[TBL] [Abstract][Full Text] [Related]
4. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
[TBL] [Abstract][Full Text] [Related]
6. Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.
Kishk SM; Kishk RM; Yassen ASA; Nafie MS; Nemr NA; ElMasry G; Al-Rejaie S; Simons C
Molecules; 2020 Oct; 25(21):. PubMed ID: 33137894
[TBL] [Abstract][Full Text] [Related]
7. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
8. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
[TBL] [Abstract][Full Text] [Related]
9. Targeting mechanism for SARS-CoV-2
Zhao X; Luo S; Huang K; Xiong D; Zhang JZH; Duan L
Nanoscale; 2021 Nov; 13(45):19218-19237. PubMed ID: 34787160
[TBL] [Abstract][Full Text] [Related]
10. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine.
Zhigulin AS; Barygin OI
Eur J Pharmacol; 2022 Mar; 919():174795. PubMed ID: 35122868
[TBL] [Abstract][Full Text] [Related]
12. The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.
Yamaya M; Shimotai Y; Hatachi Y; Lusamba Kalonji N; Tando Y; Kitajima Y; Matsuo K; Kubo H; Nagatomi R; Hongo S; Homma M; Nishimura H
Pulm Pharmacol Ther; 2015 Aug; 33():66-74. PubMed ID: 26166259
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
Zhu H; Du W; Song M; Liu Q; Herrmann A; Huang Q
Comput Struct Biotechnol J; 2021; 19():467-476. PubMed ID: 33505639
[TBL] [Abstract][Full Text] [Related]
14. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
[TBL] [Abstract][Full Text] [Related]
15. Role for HtrA in stress induction and virulence potential in Listeria monocytogenes.
Stack HM; Sleator RD; Bowers M; Hill C; Gahan CG
Appl Environ Microbiol; 2005 Aug; 71(8):4241-7. PubMed ID: 16085809
[TBL] [Abstract][Full Text] [Related]
16. [Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro].
Ino Y; Suzuki K; Sato T; Iwaki M
Nihon Yakurigaku Zasshi; 1986 Dec; 88(6):449-55. PubMed ID: 2435641
[TBL] [Abstract][Full Text] [Related]
17. Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation.
Fraser BJ; Beldar S; Seitova A; Hutchinson A; Mannar D; Li Y; Kwon D; Tan R; Wilson RP; Leopold K; Subramaniam S; Halabelian L; Arrowsmith CH; Bénard F
Nat Chem Biol; 2022 Sep; 18(9):963-971. PubMed ID: 35676539
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitors targeting coronavirus and filovirus entry.
Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
[TBL] [Abstract][Full Text] [Related]
20. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):997-1007. PubMed ID: 33062952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
